ATE276761T1 - Vorbeugung von typ-1 diabetes und anderen nicht- polio enteroviren - Google Patents

Vorbeugung von typ-1 diabetes und anderen nicht- polio enteroviren

Info

Publication number
ATE276761T1
ATE276761T1 AT00912706T AT00912706T ATE276761T1 AT E276761 T1 ATE276761 T1 AT E276761T1 AT 00912706 T AT00912706 T AT 00912706T AT 00912706 T AT00912706 T AT 00912706T AT E276761 T1 ATE276761 T1 AT E276761T1
Authority
AT
Austria
Prior art keywords
type
opv
killed
polio
prevention
Prior art date
Application number
AT00912706T
Other languages
English (en)
Inventor
Heikki Hyoety
Mikael Knip
Original Assignee
Heikki Hyoety
Mikael Knip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heikki Hyoety, Mikael Knip filed Critical Heikki Hyoety
Application granted granted Critical
Publication of ATE276761T1 publication Critical patent/ATE276761T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00912706T 1999-06-24 2000-03-17 Vorbeugung von typ-1 diabetes und anderen nicht- polio enteroviren ATE276761T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14087299P 1999-06-24 1999-06-24
PCT/FI2000/000220 WO2001000236A1 (en) 1999-06-24 2000-03-17 Prevention of type 1 diabetes and other non-polio enterovirus diseases

Publications (1)

Publication Number Publication Date
ATE276761T1 true ATE276761T1 (de) 2004-10-15

Family

ID=22493179

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00912706T ATE276761T1 (de) 1999-06-24 2000-03-17 Vorbeugung von typ-1 diabetes und anderen nicht- polio enteroviren

Country Status (10)

Country Link
EP (1) EP1187631B1 (de)
AT (1) ATE276761T1 (de)
AU (1) AU770922B2 (de)
CA (1) CA2376923C (de)
DE (1) DE60014077T2 (de)
DK (1) DK1187631T3 (de)
ES (1) ES2228481T3 (de)
NO (1) NO328680B1 (de)
PT (1) PT1187631E (de)
WO (1) WO2001000236A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8961982B2 (en) * 2005-12-16 2015-02-24 The Regents Of The University Of California Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer
FI20075063A0 (fi) * 2007-02-01 2007-02-01 Vactech Oy Allergisen herkistymisen estäminen
FI20075861A0 (fi) 2007-11-30 2007-11-30 Vactech Oy Enteroviruksen käyttö taudin diagnostiikassa, hoidossa ja ehkäisyssä
US20110245179A1 (en) * 2008-09-17 2011-10-06 Woo Jin Park Composition for Prevention or Treatment of Heart Failure
EP2402029A1 (de) 2010-07-01 2012-01-04 Sanofi Pasteur Enterovirus-Impfstoffe zur Vorbeugung oder Behandlung von Typ-1-Diabetes (III)
ES2614251T3 (es) 2010-07-01 2017-05-30 Vactech Oy Análisis de diagnóstico para diabetes tipo 1
EP2402028A1 (de) 2010-07-01 2012-01-04 Sanofi Pasteur Enterovirus-Impfstoffe zur Vorbeugung und Behandlung von Typ-1-Diabetes (II)
EP2402027A1 (de) 2010-07-01 2012-01-04 Sanofi Pasteur Enterovirus-Impfstoffe zur Vorbeugung oder Behandlung von Typ-1-Diabetes (I)
EP2583688A1 (de) 2011-10-18 2013-04-24 Sanofi Pasteur Multi-CBV-Impfstoffe zur Vorbeugung oder Behandlung von Typ-1-Diabetes
AU2012339560B2 (en) 2011-11-18 2017-03-09 Colin Dunlop A method and apparatus for facilitating delivery of anaesthetic
US20140271718A1 (en) 2013-03-15 2014-09-18 University Of Florida Research Foundation Incorporated Novel type 1 diabetes vaccines, and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728385A (en) * 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae

Also Published As

Publication number Publication date
EP1187631A1 (de) 2002-03-20
AU3436600A (en) 2001-01-31
ES2228481T3 (es) 2005-04-16
NO20016211D0 (no) 2001-12-18
DK1187631T3 (da) 2005-01-24
DE60014077D1 (de) 2004-10-28
CA2376923A1 (en) 2001-01-04
WO2001000236A1 (en) 2001-01-04
EP1187631B1 (de) 2004-09-22
CA2376923C (en) 2014-08-05
NO20016211L (no) 2002-02-20
AU770922B2 (en) 2004-03-11
PT1187631E (pt) 2005-01-31
NO328680B1 (no) 2010-04-26
DE60014077T2 (de) 2005-10-20

Similar Documents

Publication Publication Date Title
BR0009267A (pt) Tratamento da hepatite c com o uso da hipertermia
AP1771A (en) 3'-Prodrugs of 2'-deoxy-?-L-nucleosides.
Wiktor Cell-mediated immunity and postexposure protection from rabies by inactivated vaccines of tissue culture origin
BRPI0309631A2 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3,e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
DE60014077D1 (de) Vorbeugung von typ-1 diabetes und anderen nicht-polio enteroviren
NO20090865L (no) Vaksine
EA200700243A1 (ru) Способы лечения гепатита с
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
WO2007025043A3 (en) Seven-membered ring nucleosides
EA200700496A1 (ru) Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита
JPS5663922A (en) Feline infectious peritonitis virus* vaccine obtained therefrom* its manufacture and use
WO2001097824A3 (de) Verwendung von phyllanthusbestandteilen zur behandlung oder prophylaxe von infekten durch flaviviridae
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
ES2113910T3 (es) Procedimiento para la preparacion de un concentrado de trombina asegurado contra virus.
DK8789D0 (da) Fremgangsmaade til fremstilling af modificerede, staerkt afsvaekkede rna-virusstammer samt vaccine og dens anvendelse
DK0383433T3 (da) Svækkede vira
ATE401392T1 (de) Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion
BR0101523A (pt) Pestivìrus, vacina, e, processos para imunizarcontra doença induzida por pestivìrus e parafabricar uma vacina para a proteção de um animalcontra um pestivìrus
RU2002118650A (ru) Штамм № 1737/Грузия/2000 вируса ящура типа Азия-1 для изготовления диагностических и вакцинных препаратов
DK1132466T3 (da) Kyllingeanæmivira med lav patogenicitet
Centers for Disease Control and Prevention (CDC Progress toward poliomyelitis eradication--Myanmar, 1996-1999
FI893346A0 (fi) Icke-reverterande rna-virus.
Sabin et al. Landmark article Aug 6, 1960: Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. By Albert B. Sabin, Manuel Ramos-Alvarez, José Alvarez-Amezquita, William Pelon, Richard H. Michaels, Ilya Spigland, Meinrad A. Koch, Joan M. Barnes, and Johng S. Rhim
Centers for Disease Control and Prevention (CDC Progress toward poliomyelitis eradication--Nigeria, January 2008-July 2009
Malyshkina Enteroviruses in the XX and XXI centuries

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1187631

Country of ref document: EP